BioMarin Pharmaceutical Inc. said an experimental treatment for Morquio A Syndrome, a rare genetic disease, succeeded in a clinical trial. The disease causes systemic skeletal dysplasia, short stature, and joint abnormalities, which limit mobility and endurance.